Medical/Pharmaceuticals
Datasea Reports Second Fiscal Quarter 2026 Results
Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...
2026-02-12 22:20
13153
Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...
2026-02-12 22:00
5448
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Associa...
2026-02-12 15:01
4843
WuXi Vaccines Receives Brazil's ANVISA GMP Certification
SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish f...
2026-02-12 11:48
4988
Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These i...
2026-02-11 17:01
6113
PharmaResearch Announces Supply Agreement for Rejuran in Brazil
SEONGNAM, South Korea, Feb. 11, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEOJihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreement for Rejuran with DermaDream, a Brazilian aesthetic company, as part of its preparations for ent...
2026-02-11 14:54
4359
On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. Th...
2026-02-10 21:07
5614
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceuti...
2026-02-10 21:00
6487
GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services
YONGIN, South Korea, Feb. 10, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a data-driven clinical trial services provider, and Medicover Integrated Clinical Services (MICS), part of Medicover, an international healthcare and diagnostic services company, have signed a Memorandum of Understanding (M...
2026-02-10 17:27
4806
WAT Medical's EmeTerm Wearable Device Demonstrates Superior Control of Moderate to Severe Postoperative Nausea and Vomiting in JAMA Surgery-Published Clinical Trial
VANCOUVER, BC, Feb. 9, 2026 /PRNewswire/ -- WAT Medical is proud to announce the publication of a landmark randomized clinical trial inJAMA Surgery, one of the world's most reputable and high-impact surgical journals. The study confirms that the EmeTerm wristband — a wearable device utilizing tr...
2026-02-10 03:08
6322
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
* BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. * BioDlink enabled IND approval 1.5 months ahead of schedule throu...
2026-02-09 21:00
5623
Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System
HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developedGeminiOne Transcatheter Edge-to-Edge Repair (TEER) System f...
2026-02-09 14:00
6054
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2026-02-08 18:05
6268
Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone
* Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis * Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelera...
2026-02-06 22:00
10141
Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
* Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards * Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals * Validated system provides reliable, consistent carbon footprint data for clients I...
2026-02-06 21:00
9337
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment ofHalle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Z...
2026-02-06 21:00
8036
LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders
BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2026-02-06 20:00
9386
Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...
2026-02-06 20:00
6314
Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
BASKING RIDGE, N.J., Feb. 6, 2026 /PRNewswire/ -- Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequi...
2026-02-06 19:59
4347
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO:Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial inthe United ...
2026-02-06 15:20
5765
Week's Top Stories
Most Reposted
Global virtual travel card program launched by Visa and Trip.com to make travel payments simpler and more seamless in Asia Pacific
[Picked up by 331 media titles]
2026-03-11 11:08Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 299 media titles]
2026-03-10 09:00
PDG Targets USD 5 Billion Debt Raise
[Picked up by 297 media titles]
2026-03-11 10:00The Mastercard Collection: Savor the Extraordinary with Mastercard's Asia Gourmet Circle Program
[Picked up by 295 media titles]
2026-03-12 09:00Travel providers to accept UnionPay cards for both direct e-Commerce bookings and in-direct sales via Amadeus Travel Platform
[Picked up by 283 media titles]
2026-03-12 11:00
Most Read
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
2026-03-10 09:00
6749
